{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:28:09Z","timestamp":1792621689686,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006462","name":"City University of New York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.exphem.2026.105382","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T23:18:06Z","timestamp":1769901486000},"page":"105382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8821-0210","authenticated-orcid":false,"given":"Bianca","family":"Rivera-Pe\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samarpana","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-5590","authenticated-orcid":false,"given":"Yang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhamsh Reddy","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachiben P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5335-0046","authenticated-orcid":false,"given":"Shanisha Gordon","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kith","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4043-7518","authenticated-orcid":false,"given":"Xiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8489-7668","authenticated-orcid":false,"given":"Isidora","family":"To\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Aluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0816-6922","authenticated-orcid":false,"given":"Michael","family":"Wysota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya","family":"Varshavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Carbajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Ramachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Sidoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-8364","authenticated-orcid":false,"given":"David A.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-1031","authenticated-orcid":false,"given":"Yogen","family":"Saunthararajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-8288","authenticated-orcid":false,"given":"Aditi","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105382_bib0001","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3390\/curroncol31050175","article-title":"A brief overview of the molecular landscape of myelodysplastic neoplasms","volume":"31","author":"Abdulbaki","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.exphem.2026.105382_bib0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2026.105382_bib0003","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1182\/blood-2016-10-696062","article-title":"Stem and progenitor cell alterations in myelodysplastic syndromes","volume":"129","author":"Shastri","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105382_bib0004","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/d41573-024-00102-7","article-title":"FDA approves first telomerase inhibitor","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2026.105382_bib0005","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.3390\/cancers13205084","article-title":"Novel molecular mechanism of lenalidomide in myeloid malignancies independent of deletion of chromosome 5q","volume":"13","author":"Park","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2026.105382_bib0006","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/hematology.2022000350","article-title":"Targeting inflammation in lower-risk MDS","volume":"2022","author":"Gonzalez-Lugo","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2026.105382_bib0007","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","article-title":"Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions","volume":"27","author":"Zavras","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2026.105382_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101521","article-title":"Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors","volume":"36","author":"Desai","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2026.105382_bib0009","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2026.105382_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719847059","article-title":"Management of myelodysplastic syndromes after failure of response to hypomethylating agents","volume":"10","author":"Gil-Perez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.exphem.2026.105382_bib0011","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.exphem.2026.105382_bib0012","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105382_bib0013","article-title":"Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML)","volume":"9","author":"Sallman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105382_bib0014","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105382_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7054","article-title":"Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes","volume":"39","author":"Zeidan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105382_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.650473","article-title":"Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter","volume":"11","author":"Kordella","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.exphem.2026.105382_bib0017","first-page":"2989","article-title":"Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer","volume":"33","author":"Gnyszka","year":"2013","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.exphem.2026.105382_bib0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2026.105382_bib0019","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/leu.2011.159","article-title":"p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia","volume":"25","author":"Ng","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105382_bib0020","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1172\/JCI78789","article-title":"Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes","volume":"125","author":"Saunthararajah","year":"2015","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.exphem.2026.105382_bib0021","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-aza-2\u2032-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105382_bib0022","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/sj.cgt.7700358","article-title":"Momparler RL. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene","volume":"8","author":"Beaus\u00e9jour","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.exphem.2026.105382_bib0023","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105382_bib0024","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105382_bib0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/hematology.2019000042","article-title":"MDS, is higher risk higher reward?","volume":"2019","author":"In","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"10.1016\/j.exphem.2026.105382_bib0026","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1093\/hmg\/ddr338","article-title":"Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways","volume":"20","author":"Takakura","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.exphem.2026.105382_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101531","article-title":"The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase","volume":"298","author":"Heppler","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2026.105382_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115971","article-title":"Investigating the anti-cancer potential of pyrimethamine analogues through a modern chemical biology lens","volume":"264","author":"Brown","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.exphem.2026.105382_bib0029","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1038\/s41388-021-01695-8","article-title":"Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential","volume":"40","author":"Zhao","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2026.105382_bib0030","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1016\/S0021-9258(17)43186-3","article-title":"The functional human dihydrofolate reductase gene","volume":"259","author":"Chen","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2026.105382_bib0031","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fcimb.2018.00360","article-title":"A perspective on thiazolidinone scaffold development as a new therapeutic strategy for toxoplasmosis","volume":"8","author":"Rocha-Roa","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.exphem.2026.105382_bib0032","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/leu.2009.296","article-title":"Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis","volume":"24","author":"Matsuoka","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105382_bib0033","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/leu.2013.372","article-title":"An MDS xenograft model utilizing a patient-derived cell line","volume":"28","author":"Rhyasen","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105382_bib0034","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.exphem.2026.105382_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-026-02883-9","article-title":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia","author":"Chakraborty","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105382_bib0036","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2026.105382_bib0037","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: A Hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2026.105382_bib0038","doi-asserted-by":"crossref","first-page":"D1539","DOI":"10.1093\/nar\/gkac1040","article-title":"The ProteomeXchange Consortium at 10 years: 2023 update","volume":"51","author":"Deutsch","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2026.105382_bib0039","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1074\/mcp.O115.050229","article-title":"PRIDE Inspector Toolsuite: moving towards a universal visualization tool for proteomics data standard formats and quality assessment of ProteomeXchange datasets","volume":"15","author":"Perez-Riverol","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.exphem.2026.105382_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2021.338880","article-title":"High throughput and low bias DNA methylation and hydroxymethylation analysis by direct injection mass spectrometry","volume":"1180","author":"Sun","year":"2021","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.exphem.2026.105382_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2021.101585","article-title":"DNA methylation and hydroxymethylation analysis using a high throughput and low bias direct injection mass spectrometry platform","volume":"8","author":"Sun","year":"2021","journal-title":"MethodsX"},{"key":"10.1016\/j.exphem.2026.105382_bib0042","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1172\/JCI120156","article-title":"Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells","volume":"128","author":"Shastri","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2026.105382_bib0043","doi-asserted-by":"crossref","first-page":"eadj9479","DOI":"10.1126\/sciadv.adj9479","article-title":"Folate depletion induces erythroid differentiation through perturbation of de novo purine synthesis","volume":"10","author":"Maynard","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.exphem.2026.105382_bib0044","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3390\/cancers16071387","article-title":"Oncogenic STAT transcription factors as targets for cancer therapy: innovative strategies and clinical translation","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2026.105382_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","article-title":"Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review","volume":"17","author":"Ben-Harari","year":"2017","journal-title":"Drugs R D"},{"key":"10.1016\/j.exphem.2026.105382_bib0046","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archopht.1960.01840010142016","article-title":"The hematologic toxicity of pyrimethamine (daraprim) in man","volume":"64","author":"Kaufman","year":"1960","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.exphem.2026.105382_bib0047","doi-asserted-by":"crossref","first-page":"E95","DOI":"10.1002\/ajh.26084","article-title":"Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses","volume":"96","author":"Brown","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2026.105382_bib0048","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-017-2057-0","article-title":"The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer","volume":"67","author":"Khan","year":"2018","journal-title":"Cancer Immunol Immunother"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:13:24Z","timestamp":1777547604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":48,"alternative-id":["S0301472X26000159"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105382","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Experimental Hematology.","name":"copyright","label":"Copyright"}],"article-number":"105382"}}